EGFR Inhibitors
4
- “Ocular Adverse Events of Systemic Inhibitors of the Epidermal Growth Factor Receptor: Report of 5 Cases” Ophthalmology (2012)
- “Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study”, Frontiers in Oncology (2020)
- “Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review”, Supportive Care in Cancer (2012)
- “Ocular Toxicities of Epidermal Growth Factor Receptor Inhibitors and Their Management”, Cancer Nursing (2007)
MEK Inhibitors
7
- “Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database”, Ophthalmology (2021)
- “OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS”, Retina (2019)
- “New features in MEK retinopathy”, BMC Ophthalmology (2018)
- “Ocular toxicity due to Trametinib and Dabrafenib”, BMC Ophthalmology (2017)
- “Ocular toxicities of MEK inhibitors and other targeted therapies”, Annals of Oncology (2016)
- “MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity”, Eye (2015)
- “Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities”, Cancer Treatment Reviews (2013)